NeuroPace (NPCE) Company Overview

MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5th – 9th in San Diego.

– 2025 revenue guidance of $92 million to $96 million – – 2025 gross margin guidance of 73% to 75% – – Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today issued 2025 financial guidance targets at an in-person and virtual Investor Day today in New York, New York (a replay can be viewed virtually here, and the accompanying slide presentation can be accessed here).

NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024

NeuroPace (NPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference.

MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will host an Investor Day from 9:00 a.m. – 12:00 p.m. ET on Tuesday, January 28, 2025 in New York City.

Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy

NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.